Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
The use of remdesivir (Veklury, Gilead) can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.
Using the treatment promptly in these patients can provide a significant survival benefit, and is effective across all virus variants, said the authors of a recent report (Clin Infect Dis 2023;77[12]:1626-1634.https://doi.org/10.1093/cid/ciad460).
“Upon